MRNA Moderna Inc

By Michael Dabaie

Moderna Inc. shares rose 3% to $180.44 Tuesday after the company said it is expanding its mRNA pipeline with two new development programs, including a combination vaccine program.

Programs include a combination respiratory vaccine candidate and a new program against all four of the endemic human coronaviruses, according to the company.

Moderna said it is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate, mRNA-1230, is envisioned as an annual booster targeting SARS-CoV-2, influenza and respiratory syncytial virus, the company said.

Moderna also said it is introducing a program to develop a vaccine candidate, mRNA-1287, against endemic human coronaviruses, or HCoVs.

"Our goal is to develop vaccines to address respiratory infections, and eventually combine many into a single annual booster vaccine with the aim of reducing the significant morbidity and mortality caused by these viruses," said President Stephen Hoge.

Moderna said it is unveiling the programs ahead of its 3RD Annual Vaccines Day, which is scheduled for Thursday.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

March 22, 2022 13:14 ET (17:14 GMT)

Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024